ATTACHMENT B FEE SCHEDULE_RFP.xlsx
XLSX spreadsheet 275 KB Posted
- Attached to
- Q301--VISN22 | REFERENCE LAB TESTING
- Solicitation number
- 36C26226R0001
About this file
This file is a detailed fee schedule (Attachment B) for a Reference Lab Testing contract with the Department of Veterans Affairs, Veterans Health Administration, Veterans Integrated Service Network 22 (VISN 22). The extensive spreadsheet contains 1,652 individual laboratory test line items across three major categories: General Tests, Allergens, and Complex Antibodies, with estimated quantities for a base year and four option years.
The fee schedule covers an exhaustive range of laboratory tests including clinical chemistry, immunology, microbiology, molecular diagnostics, toxicology, and specialized antibody panels. Each test entry includes estimated quantities per year, with pricing columns for the base year and subsequent option years. While the unit prices are currently listed as zero ($0), the document provides a comprehensive catalog of potential reference laboratory testing services that could be performed under the contract. The tests range from routine screenings like complete blood counts and metabolic panels to highly specialized tests such as genetic mutation analyses, autoimmune antibody panels, and advanced molecular diagnostics.
View the file
Other files
Show all 15
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
PRICE GENERAL B - OY4
| No. | Test Description | Estimated Quantity | Unit Price Base Year | Extended Price Base Year | Unit Price OY 1 | Extended Price OY 1 | Unit Price OY 2 | Extended Price OY 2 | Unit Price OY 3 | Extended Price OY 3 | Unit Price OY 4 | Extended Price OY 4 | Total Base Year to OY 4 |
| 1 | 11-DEOXYCORTISOL | 6 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 2 | 14-3-3 Protein, CSF (Prion Disease) | 7 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 3 | 17-Hydroxycorticosteroids, Urine | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 4 | 17-Hydroxypregnenolone | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 5 | 17-HYDROXYPROGESTERONE | 150 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 6 | 17-Hydroxyprogesterone Neonatal/Infant | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 7 | 2,3-Dinor-11 Beta-Prostaglandin F2 Alpha, 24 Hour, Urine | 25 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 8 | 21- Hydroxylase Antibody | 17 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 9 | 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (HMGCR) Antibody (IgG) | 50 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 10 | 5' Nucleotidase | 54 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 11 | 5-HIAA, PLASMA | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 12 | 5-Hydroxyindoleacetic Acid (5-HIAA), 24-Hour Urine, with Creatinine | 125 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 13 | Alpha-1 Antitrypsin (AAT) Mutation Analysis | 4 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 14 | ABL Kinase Domain Mutation in CML, Cell-based | 15 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 15 | AccuType® CP, Clopidogrel CYP2C19 Genotype | 30 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 16 | Angiotensin Converting Enzyme | 175 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 17 | Acid-Fast Bacilli ID, Sequencing and Stain, Paraffin Block | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 18 | ACTH, Plasma | 1000 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 19 | Actin (Smooth Muscle) Antibody (IgG) | 175 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 20 | Activated Protein C Resistance with Reflex to Factor V (Leiden) Mutation | 12 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 21 | Activated Protein C-Resistance | 80 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 22 | Acyclovir, Serum/Plasma | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 23 | Acylcarnitine, Plasma | 14 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 24 | Adalimumab Anti-drug Antibody for IBD | 100 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 25 | Adalimumab Anti-drug Antibody for Rheumatic Diseases | 30 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 26 | Adalimumab Drug Level and Anti-drug Antibody for IBD | 33 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 27 | Adalimumab Level for IBD | 100 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 28 | Adalimumab Level for Rheumatic Diseases | 33 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 29 | ADAMTS13 Activity with Reflex to Inhibitor | 50 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 30 | Adenosine Deaminase, CSF | 6 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 31 | Adenosine Deaminase, Peritoneal Fluid | 26 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 32 | Adenosine Deaminase, Pleural Fluid | 200 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 33 | Adenosine Deaminase, RBC | 4 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 34 | Adenovirus Antibody, Serum | 60 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 35 | Adenovirus Antigen Detection, Gastroenteritis, EIA | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 36 | Adenovirus DNA, Qualitative, Real-Time PCR | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 37 | Adenovirus DNA, Quantitative Real-Time PCR | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 38 | ADmark® ApoE Genotype Analysis and Interpretation (Symptomatic) | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 39 | Adrenal Antibody Screen with Reflex to Titer | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 40 | Advanced Lipid Panel, Cardio IQ® | 7 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 41 | Alanine Aminotransferase (ALT) | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 42 | ALBUMIN | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 43 | Albumin, CSF | 7 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 44 | Albumin, Peritoneal Fluid | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 45 | Albumin, Pleural Fluid | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 46 | Albumin, Pericardial Fluid | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 47 | Alcohol, Isopropyl | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 48 | Alcohol, Methyl | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 49 | ALDOLASE | 800 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 50 | Aldosterone, 24-Hour Urine | 40 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 51 | Aldosterone, LC/MS/MS | 800 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 52 | Aldosterone/Cortisol Ratio, Adrenal Vein Sampling, 1 Site | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 53 | Aldosterone/Cortisol Ratio, Adrenal Vein Sampling, 2 Sites | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 54 | Aldosterone/Cortisol Ratio, Adrenal Vein Sampling, 5 Sites | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 55 | Aldosterone/Cortisol Ratio, Adrenal Vein Sampling, 3 Sites | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 56 | Aldosterone/Cortisol Ratio, Adrenal Vein Sampling, 4 Sites | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 57 | Aldosterone/Cortisol Ratio, Adrenal Vein Sampling, 6 Sites | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 58 | Aldosterone/Cortisol Ratio, Adrenal Vein Sampling, 7 Sites | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 59 | Aldosterone/Cortisol Ratio, Adrenal Vein Sampling, 8 Sites | 4 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 60 | Aldosterone/Plasma Renin Activity Ratio, LC/MS/MS | 253 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 61 | Alkaline Phosphatase Isoenzymes | 680 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 62 | Alkaline Phosphatase, Bone Specific | 300 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 63 | Allopurinol and Metabolite, Serum/Plasma | 25 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 64 | Alpha Defensin, Synovial Fluid, LFA | 4 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 65 | Alpha Subunit | 20 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 66 | Alpha-1-Antitrypsin (AAT) Phenotype | 420 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 67 | Alpha-1-Antitrypsin, Feces, 24-Hour | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 68 | Alpha-1-Antitrypsin, Quantitative | 2000 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 69 | Alpha-1-Antitrypsin, Random Feces | 13 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 70 | Alpha-2-Antiplasmin | 14 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 71 | Alpha-2-Macroglobulin | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 72 | Alpha-Galactosidase, Serum | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 73 | Alpha-Globin Common Mutation Analysis | 40 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 74 | Alpha-Globin Gene Deletion or Duplication | 9 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 75 | Alpha-Fetoprotein (AFP) and AFP-L3 | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 76 | Alprazolam (Xanax) | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 77 | Alternative Complement Pathway Activity | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 78 | Aluminum | 175 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 79 | Aluminum, Blood | 6 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 80 | Amikacin | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 81 | Amikacin, Peak | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 82 | Amikacin, Trough | 6 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 83 | Amino Acid Analysis, LC/MS, Urine | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 84 | Amino Acid Analysis, Plasma | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 85 | Amiodarone | 12 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 86 | Amitriptyline | 20 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 87 | AML1/ETO t(8;21) Quantitative, Real-Time PCR | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 88 | Amphetamines Expanded, Quantitative, Urine | 2200 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 89 | Amylase Isoenzymes with Reflex to Macroamylase | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 90 | Amylase, Pancreatic Cyst | 30 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 91 | Amylase, Peritoneal Fluid | 40 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 92 | Amylase, Pleural Fluid | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 93 | ANA Screen,IFA, with Reflex to Titer and Pattern | 4000 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 94 | Anaerobic Bacteria Identification and Susceptibility | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 95 | Anaplasma phagocytophilum and Ehrlichia chaffeensis Antibody Panel | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 96 | Anaplasma phagocytophilum Antibodies (IgG, IgM) | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 97 | Anaplasma phagocytophilum DNA, Qualitative Real-Time PCR | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 98 | Anaplastic Lymphoma Kinase 1 (ALK1), IHC with Interpretation | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 99 | ANCA Screen with MPO and PR3, with Reflex to ANCA Titer | 620 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 100 | ANCA Screen with Reflex to ANCA Titer | 1200 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 101 | Androstenedione | 40 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 102 | Angiotensin Converting Enzyme | 520 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 103 | Angiotensin Converting Enzyme (ACE), CSF | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 104 | Anise (f271) IgE | 4 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 105 | Anti-GP-210 Ab | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 106 | Antimicrobial Susceptibility Panel, Anaerobic Bacteria, MIC (Gradient) | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 107 | Antimicrobial Susceptibility, Aerobic Bacteria, Custom MIC (3) | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 108 | Antimicrobial Susceptibility, AFB, Rapid Grower, MIC | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 109 | Antimicrobial Susceptibility, Anaerobic Bacteria, 1 Drug, MIC | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 110 | Antimicrobial Susceptibility, Anaerobic Bacteria, 3 Drug, MIC | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 111 | Antimicrobial Susceptibility, Nocardia/Aerobic Actinomycetes, MIC | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 112 | Anti-Mullerian Hormone (AMH), Female | 225 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 113 | Anti-Mullerian Hormone (AMH), Male | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 114 | Antiphospholipid Antibody Panel | 140 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 115 | Anti-Streptolysin O Antibody (ASO) | 80 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 116 | Antithrombin III Activity | 250 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 117 | Antithrombin III Antigen | 230 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 118 | Apixaban | 115 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 119 | Apolipoprotein A1 | 7 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 120 | Apolipoprotein B | 9 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 121 | Apolipoprotein Evaluation | 115 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 122 | Apolipoprotein L1 (APOL1) Renal Risk Variant Genotyping | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 123 | Aripiprazole, Quantitative, Serum/Plasma | 15 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 124 | Arsenic, 24-Hour Urine | 45 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 125 | Arsenic, Blood | 215 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 126 | Arsenic, Urine | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 127 | Aspartate Aminotransferase (AST) | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 128 | Aspergillus Antibody Panel, CF and ID, Serum | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 129 | Aspergillus Antibodies, Immunodiffusion, Serum | 206 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 130 | Aspergillus Antigen, EIA, BAL | 225 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 131 | Aspergillus Antigen, EIA, Serum | 510 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 132 | Aspergillus DNA, Qualitative, Real-Time PCR | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 133 | Aspergillus fumigatus (IgG) Antibody | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 134 | Babesia duncani (WA1) Antibody (IgG), IFA | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 135 | Babesia microti Antibodies (IgG, IgM), IFA | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 136 | Babesia microti DNA, Real-Time PCR | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 137 | Baclofen, Serum/Plasma | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 138 | Bacteria Identification, Aerobic | 15 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 139 | Bacterial 16S rDNA Sequencing | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 140 | Bacterial Identification and Susceptibility, Aerobic | 52 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 141 | Bacterial Identification, Anaerobic | 12 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 142 | Bartonella DNA, Qualitative Real-Time PCR | 12 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 143 | Bartonella henselae Antibodies (IgG, IgM) with Reflext to Titers | 52 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 144 | Bartonella quintana Antibodies (IgG, IgM) with Reflex to Titers | 35 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 145 | Bartonella Species Antibodies (IgG, IgM) with Reflex to Titers | 20 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 146 | Basic Metabolic Panel | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 147 | B-cell Clonality Panel (IGH, IGK), PCR | 80 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 148 | B-cell Receptor IGH Gene Rearrangement, PCR | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 149 | BCR-ABL1 Gene Rearrangement, Quantitative, PCR | 42 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 150 | Benzodiazepines, Serum | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 151 | Beta Globin Gene Dosage Analysis | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 152 | Beta-2 Transferrin, Body Fluid | 8 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 153 | Beta-2-Glycoprotein I Antibodies (IgG, IgA, IgM) | 200 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 154 | Beta-2-Glycoprotein I Antibody (IgA) | 420 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 155 | Beta-2-Glycoprotein I Antibody (IgG) | 400 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 156 | Beta-2-Glycoprotein I Antibody (IgM) | 420 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 157 | Beta-2-Microglobulin, Serum | 440 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 158 | Beta-2-Microglobulin, Urine | 6 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 159 | Beta-Amyloid 42/40 Ratio, CSF | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 160 | Beta-Globin Complete™ | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 161 | Beta-Hydroxybutyrate | 9 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 162 | Bile Acids, Fractionated and Total | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 163 | Bile Acids, Total , Enzymatic | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 164 | Bilirubin, Body Fluid | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 165 | Bilirubin, Direct | 7 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 166 | Bilirubin, Total | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 167 | Biotin (Vitamin B7) | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 168 | Bird and Mold Precipitin Panel II | 80 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 169 | BK and JC Virus DNA, Qualitative, Real-Time PCR | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 170 | BK Virus DNA, Qualitative, Real-Time PCR, Plasma | 18 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 171 | BK Virus DNA, Quantitative, Real-Time PCR, Plasma | 420 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 172 | BK Virus DNA, Quantitative, Real-Time PCR, Urine | 250 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 173 | Bladder Cancer, FISH | 75 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 174 | Blastomyces Antibody, Complement Fixation, Serum | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 175 | Fungal Antibody Panel 2, ID and CF | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 176 | Blastomyces Antibody Panel, CF and ID | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 177 | Blastomyces Antibody, Immunodiffusion | 130 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 178 | Blastomyces Antibody, Complement Fixation, CSF | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 179 | Blood Urea Nitrogen, Body Fluid | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 180 | Bordetella pertussis toxin (PT) Antibodies (IgG, IgA), MAID | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 181 | Bordetella pertussis toxin (PT) Antibody (IgG), Immunoassay | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 182 | Bordetella pertussis/parapertussis DNA, Qualitative, Real-Time PCR | 8 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 183 | Borrelia Species DNA, Qualitative Real-Time PCR, Miscellaneous | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 184 | Borrelia Species DNA, Real-Time PCR, with Reflexes, Synovial Fluid/CSF | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 185 | BRAF MUTATION ANALYSIS | 13 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 186 | BRAF Mutation Analysis, Papillary Thyroid Cancer | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 187 | BRAF V600 Mutation Analysis, PCR, Cobas® | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 188 | BRCA Panel (BRCA1, BRCA2) | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 189 | Brucella Antibodies (IgG, IgM), EIA with Reflex to Agglutination | 60 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 190 | Brucella Antibody, Agglutination | 7 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 191 | Bullous Pemphigoid BP180 Antibody | 50 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 192 | Bullous Pemphigoid BP230 Antibody | 55 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 193 | Buprenorphine and Metabolites, LC/MS/MS, Serum | 35 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 194 | Buprenorphine, Quantitative, Urine | 1100 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 195 | Bupropion and Metabolite, Serum/Plasma | 104 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 196 | C1 Esterase Inhibitor, Functional | 125 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 197 | C1 ESTERASE INHIBITOR, PROTEIN | 33 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 198 | C1 Esterase Inhibitor, Protein | 106 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 199 | C1q Antibody (IgG) | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 200 | Complement Component 2 | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 201 | Complement Component C4a, Plasma | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 202 | CA 125 | 315 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 203 | CA 15-3 | 60 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 204 | CA 19-9 | 1500 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 205 | CA 27.29 | 102 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 206 | Cadmium, 24-Hour Urine | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 207 | Cadmium, Blood | 17 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 208 | Cadmium, Random Urine | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 209 | Calcitonin | 102 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 210 | Calcitriol 1,25-Dihydroxyvitamin D | 1500 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 211 | Calcium, 24-Hour Urine without Creatinine | 75 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 212 | Calcium, Ionized | 190 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 213 | Calcium, Random Urine with Creatinine | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 214 | Calcium, Random Urine without Creatinine | 40 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 215 | California Encephalitis Virus Antibody Panel, IFA, CSF | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 216 | Calprotectin, Stool | 1850 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 217 | Calreticulin (CALR) Mutation Analysis | 75 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 218 | Campylobacter jejuni Antibody, ELISA | 13 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 219 | Candida albicans Antibodies (IgG, IgA, IgM) | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 220 | Candida-induced Lymphocyte Proliferation | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 221 | Cannabinoids Panel, Serum/Plasma | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 222 | Carbamazepine and Metabolite, Total | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 223 | Carbamazepine, Total | 32 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 224 | Carboxyhemoglobin, Blood | 18 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 225 | Cardio IQ® APOE Genotype | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 226 | Cardio IQ® Apolipoprotein A-1 | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 227 | Cardio IQ® Cholesterol, Total | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 228 | Cardio IQ® CYP2C19 Genotype | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 229 | Cardio IQ® HDL Cholesterol | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 230 | Cardio IQ® hs-CRP | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 231 | Cardio IQ® Insulin | 4 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 232 | Cardio IQ® Lipoprotein Fractionation, Ion Mobility | 15 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 233 | Cardio IQ® Lp-PLA2 Activity | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 234 | Cardio IQ® Myeloperoxidase (MPO) | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 235 | Cardio IQ® NT ProBNP | 4 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 236 | Cardio IQ® Triglycerides | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 237 | Cardiolipin Antibodies (IgA, IgG, IgM) | 700 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 238 | Cardiolipin Antibodies (IgG, IgM) | 205 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 239 | Carisoprodol Screen, with Confirmation, Urine | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 240 | Carnitine | 13 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 241 | Carotene | 21 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 242 | CASPR2 Antibody Test | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 243 | Catecholamines, Fractionated, 24-Hour Urine with Creatinine | 50 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 244 | Catecholamines, Fractionated, 24-Hour Urine without Creatinine | 65 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 245 | Catecholamines, Fractionated, Plasma | 75 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 246 | Catecholamines, Fractionated, Random Urine | 7 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 247 | Cathartic Laxatives Profile, Stool | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 248 | CBC (includes Differential and Platelets) | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 249 | CBFB/MYH11 inv(16), Quantitative, Real-Time PCR | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 250 | Corticosteroid Binding Globulin (CBG) | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 251 | CDKN2A Sequencing and Deletion/Duplication | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 252 | CEA, Carcinoembryonic Antigen, Pancreatic Cyst Fluid | 26 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 253 | CEA, Peritoneal Fluid | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 254 | CEA, Pleural Fluid | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 255 | CEBPA Mutation Analysis | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 256 | Celiac Disease Comprehensive Panel | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 257 | Celiac Disease Comprehensive Panel with Gliadin Antibody (IgG) | 840 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 258 | Centromere B Antibody | 550 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 259 | Ceruloplasmin | 2300 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 260 | Chikungunya Antibodies (IgG, IgM) with Reflex to Titers | 6 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 261 | Chlamydia trachomatis Antibodies (IgG, IgA, IgM) | 60 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 262 | Chlamydia/Chlamydophila Antibody Panel 3 (IgG, IgA, IgM) | 65 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 263 | Chlamydia/Neisseria gonorrhoeae RNA, TMA, Urogenital | 12 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 264 | Chlamydophila pneumoniae Antibodies (IgG, IgA, IgM) | 8 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 265 | Chlamydophila pneumoniae, DNA, Qualitative, Real-Time PCR | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 266 | Chlamydophila psittaci Antibodies (IgG, IgA, IgM) | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 267 | Chlordiazepoxide and Metabolites | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 268 | Chloride, 24-Hour Urine without Creatinine | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 269 | Chloride, Random Urine without Creatinine | 150 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 270 | Cholesterol, Peritoneal Fluid | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 271 | Cholesterol, Pleural Fluid | 150 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 272 | Cholesterol, Total | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 273 | Cholinesterase, Plasma | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 274 | Cholinesterase, Plasma (CA Clients) | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 275 | Cholinesterase, Serum, with Dibucaine Inhibition | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 276 | Chromatin (Nucleosomal) Antibody | 550 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 277 | Chromium, Blood | 35 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 278 | Chromium, Plasma | 17 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 279 | Chromium, Serum | 21 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 280 | Chromogranin A, LC/MS/MS | 410 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 281 | Chromosomal Microarray, Postnatal, ClariSure® Oligo-SNP | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 282 | Chromosome Analysis, Blood | 45 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 283 | Chromosome Analysis, CLL/LPD | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 284 | Chromosome Analysis, Hematologic Malignancy | 450 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 285 | Chromosome Analysis, Lymph Node | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 286 | Chronic Lymphocytic Leukemia (CLL)/Lymphoma Diagnostic Panel | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 287 | Chronic Lymphocytic Leukemia (CLL)/Lymphoma Follow-up Panel | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 288 | Chronic Lymphocytic Leukemia, IgVH Mutation Status, Cell-based | 21 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 289 | Chronic Urticaria Panel 2 (Comprehensive) | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 290 | Chymotrypsin, Stool | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 291 | Circulating Immune Complex, C3 Fragments | 12 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 292 | Citric Acid, 24-Hour Urine with Creatinine | 60 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 293 | c-KIT Mutation Analysis, Cell Based | 6 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 294 | c-KIT Mutations with Reflex to PDGFRA Mutations for GIST | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 295 | CLL Profile | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 296 | Clomipramine | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 297 | Clonazepam | 11 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 298 | Clostridium difficile Cytotoxin Antibody Neutralization | 21 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 299 | Clostridium difficile Toxin B, Qualitative, Real-Time PCR | 55 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 300 | Clostridium difficile Toxin/GDH with Reflex to PCR | 130 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 301 | Clozapine | 625 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 302 | Cobalt | 45 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 303 | Cobalt, Blood | 25 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 304 | Cobalt, Random Urine | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 305 | Cocaine and Metabolites, Confirmation, Serum | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 306 | Coccidioides Antibodies (IgG, IgM), Immunodiffusion with Reflex to Complement Fixation | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 307 | Coccidioides Antibody (IgG), Immunodiffusion, Serum | 135 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 308 | Coccidioides Antibody Panel, Complement Fixation and Immunodiffusion, CSF | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 309 | Coccidioides Antibody, Complement Fixation, CSF | 20 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 310 | Coccidioides Antibody, Complement Fixation, Serum | 200 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 311 | Coenzyme Q10 | 7 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 312 | Cold Hemagglutinins | 33 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 313 | Collagen Cross-Linked N-Telopeptide (NTx), 24-Hour Urine | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 314 | Collagen Cross-Linked N-Telopeptide (NTx), Urine | 207 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 315 | Collagen Type I C-Telopeptide (CTx) | 214 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 316 | Collagen Type II Antibodies | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 317 | Complement Component C1q | 75 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 318 | Complement Component C3c | 840 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 319 | Complement Component C3c and C4c | 530 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 320 | Complement Component C4c | 900 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 321 | Complement, Total (CH50) | 175 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 322 | Comprehensive Metabolic Panel | 6 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 323 | Concanavalin A (Con A)-induced Lymphocyte Proliferation | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 324 | Copeptin | 45 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 325 | Copper | 1800 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 326 | COPPER, 24-HOUR URINE | 75 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 327 | Copper, Liver Tissue | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 328 | Copper, Random Urine | 80 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 329 | Copper, RBC | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 330 | Corticosterone | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 331 | Cortisol, Free, 24-Hour Urine | 75 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 332 | Cortisol, Free, 24-Hour Urine with Creatinine, LC/MS/MS | 180 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 333 | Cortisol, LC/MS, Saliva | 180 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 334 | Cortisol, Total | 600 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 335 | Cortisol, Total, LC/MS | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 336 | Coxiella burnetii DNA, Qualitative Real-Time PCR | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 337 | Coxsackie A Antibodies, Serum | 15 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 338 | C-Peptide | 650 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 339 | C-Reactive Protein (CRP) | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 340 | Creatine Kinase (CK), Total | 170 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 341 | Creatine Kinase Isoenzymes (CK Isoenzymes) with Total CK | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 342 | Creatine Kinase Isoenzymes (CK Isoenzymes) without Total CK | 150 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 343 | Creatine, Serum | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 344 | Creatinine | 23 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 345 | Creatinine, 24-Hour Urine | 223 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 346 | Creatinine, Random Urine | 330 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 347 | Creatinine, Peritoneal Fluid | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 348 | Cryofibrinogen | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 349 | Cryoglobulin (% Cryocrit), Serum | 180 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 350 | Cryoglobulin Screen with Reflex to Cryoglobulin Panel | 275 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 351 | Cryptococcal Antigen, Latex Screen with Reflex to Titer | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 352 | Cryptococcus Antibody | 103 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 353 | Cryptosporidium Antigen, EIA | 225 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 354 | CSF3R Mutation Analysis | 75 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 355 | Culture, Blood | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 356 | Culture, Anaerobic Bacteria with Gram Stain | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 357 | Culture, Fungus, Blood | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 358 | Culture, Fungus, Miscellaneous | 750 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 359 | Culture, Fungus, other than Hair, Skin, Blood, with Fluorescent KOH | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 360 | Culture, Fungus, Skin, Hair or Nails | 33 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 361 | Culture, Fungus, Skin, Hair, Nail with Direct Fluorescent/KOH | 24 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 362 | Culture, Viral, Non-Respiratory, Conventional, Body Fluids or Tissue | 21 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 363 | Cutaneous Direct Immunofluorescence | 43 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 364 | Cyanide, Blood | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 365 | Cyclospora and Isospora Examination | 34 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 366 | Cyclosporine A Trough, LC/MS/MS, Blood | 100 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 367 | CYCLOSPORINE A,TROUGH,B | 43 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 368 | Cystatin C with Glomerular Filtration Rate, Estimated (eGFR) | 200 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 369 | Cysticercus Antibody (IgG), ELISA, CSF | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 370 | Cysticercus Antibody (IgG), ELISA, Serum | 6 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 371 | Cysticercus Antibody (IgG), ELISA, Serum with Reflex to Western Blot | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 372 | Cysticercus Antibody (IgG), Western Blot, Serum | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 373 | Cystine, 24-Hour Urine | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 374 | Cytosolic 5'-Nucleotidase 1A (cN-1A) Antibody (IgG) | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 375 | Cytochrome P450 2D6 Genotype | 13 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 376 | Cytomegalovirus Antibody (IgG) | 60 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 377 | Cytomegalovirus Antibody (IgM) | 62 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 378 | Cytomegalovirus DNA, Qualitative, Real-Time PCR | 115 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 379 | Cytomegalovirus DNA, Quantitative, Real-Time PCR | 912 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 380 | Cytomegalovirus, Rapid Culture | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 381 | Cytosolic 5'-Nucleotidase 1A (cN-1A) Antibody (IgG) | 25 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 382 | DCP (Des-Gamma-Carboxy-Prothrombin) | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 383 | Delta Aminolevulinic Acid, 24-Hour Urine | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 384 | Delta Aminolevulinic Acid, Random Urine | 4 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 385 | Dengue Fever Antibodies (IgG, IgM) | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 386 | Dengue Fever Antibody (IgG) | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 387 | Dengue Fever Antibody (IgM) | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 388 | Dengue Virus NS1 Antigen | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 389 | Dengue Virus RNA, Qualitative, Real-Time PCR | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 390 | DEOXYCORTICOSTERONE | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 391 | Desipramine | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 392 | Desmoglein Antibodies (1 and 3) | 8 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 393 | Dexamethasone | 200 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 394 | Dextro/Levo Methorphan, LC/MS/MS, Urine | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 395 | DHEA Sulfate, Immunoassay | 750 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 396 | DHEA, (Dehydroepiandrosterone), Unconjugated | 65 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 397 | Diazepam and Metabolite | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 398 | Dihydrotestosterone | 23 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 399 | Diphtheria and Tetanus Antitoxoids | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 400 | Diphtheria Antitoxoid | 42 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 401 | Direct LDL | 55 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 402 | Diuretics Screen, Urine | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 403 | D-Lactate, Plasma | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 404 | DMPK DNA Test (DM1) | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 405 | DNA (ds) Antibody | 700 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 406 | DNA (ds) Antibody, Crithidia IFA with Reflex to Titer | 340 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 407 | DNase-B Antibody | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 408 | Doxepin | 7 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 409 | DPD Mutation Analysis | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 410 | Draw Fee, PSC Specimen | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 411 | Drug Abuse Panel 8, with Confirmation, Serum or Plasma | 270 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 412 | Drug Abuse Screen 5, without Confirmation, Serum | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 413 | Drug Abuse Screen 7, with Confirmation, Serum | 12 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 414 | Drug Monitoring, Amphetamines, Quantitative, Urine | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 415 | Drug Monitoring, Antidepressants, with Confirmation, Serum | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 416 | Drug Monitoring, Barbiturates, Quantitative, Urine | 17 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 417 | Drug Monitoring, Benzodiazepines, Quantitative, Urine | 600 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 418 | Drug Monitoring Assess Panel, Comprehensive, Qualitative, Urine | 2000 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 419 | Drug Monitoring Assess Panel, Volatiles, Urine | 2000 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 420 | Drug Monitoring, Buprenorphine and Naloxone, Quantitative, Urine | 140 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 421 | Drug Monitoring, Buprenorphine, Screen, Urine | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 422 | Drug Monitoring, Carisoprodol Metabolite, Quantitative, Urine | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 423 | Drug Monitoring, Cocaine Metabolite, Quantitative, Urine | 170 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 424 | Drug Monitoring, Fentanyl, Quantitative, Urine | 650 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 425 | Drug Monitoring, Gabapentin, Quantitative, Urine | 8 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 426 | Drug Monitoring, Heroin Metabolite, Quantitative, Urine | 6000 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 427 | Drug Monitoring, Ketamine, Quantitative, Urine | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 428 | Drug Monitoring, Marijuana Metabolite, Quantitative, Urine | 1750 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 429 | Drug Monitoring, Methadone Metabolite, Quantitative, Urine | 17 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 430 | Drug Monitoring, Methamphetamine D/L Isomers, Urine | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 431 | Drug Monitoring, Methylphenidate Metabolite, Quantitative, Urine | 15 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 432 | Drug Monitoring, Mitragynine, Quantitative, Urine | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 433 | Drug Monitoring, Novel Psychoactive Substances (NPS), Qualitative, Urine | 51 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 434 | Drug Monitoring, Opiates Expanded, Quantitative, Urine | 650 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 435 | Drug Monitoring, Opiates, Screen, Urine | 13 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 436 | Drug Monitoring, Phencyclidine, Quantitative, Urine | 20 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 437 | Drug Monitoring, Phosphatidylethanol (PEth), Blood | 225 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 438 | Drug Monitoring, Pregabalin, Quantitative, Urine | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 439 | Drug Monitoring, Propoxyphene Metabolite, Quantitative, Urine | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 440 | Drug Monitoring, Tapentadol, Quantitative, Urine | 15 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 441 | Drug Monitoring, Tramadol, Quantitative, Urine | 4300 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 442 | Drug Monitoring, Tricyclic Antidepressants, Quantitative, Urine | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 443 | Drug Monitoring, Zolpidem, Quantitative, Urine | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 444 | Drug Screen, Clinical 1, without Confirmation, Serum | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 445 | Drug Test, General Toxicology, Serum | 135 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 446 | Drug Toxicology Monitoring Alcohol Metabolites, Quantitative, Urine | 1500 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 447 | Drug Toxicology Monitoring Alcohol Metabolites, with Confirmation, Urine | 7 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 448 | Drug Toxicology Monitoring Fentanyl, Quantitative, Urine | 7 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 449 | Drug Toxicology Monitoring Tapentadol, Quantitative, Urine | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 450 | Drug Toxicology Monitoring, Fentanyl, with Confirmation, Urine | 22566 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 451 | dRVVT Screen with Reflex to dRVVT Confirm and dRVVT 1:1 Mix | 387 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 452 | Duloxetine, Serum/Plasma | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 453 | Eastern Equine Encephalitis Virus Antibody, IFA, CSF | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 454 | Echinococcus Antibody (IgG), EIA with Reflex to Western Blot | 50 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 455 | Echovirus Antibody Panel | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 456 | Ehrlichia chaffeensis (IgG, IgM) | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 457 | Ehrlichia chaffeensis DNA, Real-Time PCR | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 458 | Electrolytes, Feces | 42 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 459 | Encephalitis Antibody Evaluation with Reflex to Titer and Line Blot, CSF | ||||||||||||
| 460 | Encephalitis Antibody Evaluation with Reflex to Titer and Line Blot, Serum | ||||||||||||
| 461 | Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid | ||||||||||||
| 462 | Endomysial Antibody (IgA) Screen with Reflex to Titer | 160 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 463 | Enhanced Liver Fibrosis (ELF) Score | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 464 | Entamoeba histolytica Antibody (IgG), ELISA | 35 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 465 | Enterovirus RNA, Qualitative, Real-Time PCR | 40 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 466 | Enterovirus/Parechovirus RNA, Qualitative Real-Time PCR | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 467 | Epidermal Antibodies with Reflex to Titer | 27 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 468 | Epidermal Growth Factor Receptor (EGFR) Mutation Analysis | 4 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 469 | Epilepsy Antibody Evaluation with Reflex to Titer and Line Blot, CSF | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 470 | Epstein Barr Virus DNA, Qualitative, Real-Time PCR | 12 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 471 | Epstein-Barr Virus Antibody Panel | 70 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 472 | Epstein-Barr Virus DNA, Quantitative, Real-Time PCR | 255 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 473 | Epstein-Barr Virus Nuclear Antigen (EBNA) Antibody (IgG) | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 474 | Epstein-Barr Virus, ISH with Interpretation | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 475 | ER/PR, Paraffin Block | 12 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 476 | ER/PR/HER2 with Reflex to HER2 FISH, Paraffin Block | 9 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 477 | Erythrocyte Porphyrin (EP), Whole Blood | 13 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 478 | Erythropoietin | 1100 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 479 | Escitalopram, Serum/Plasma | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 480 | Eslicarbazepine | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 481 | Estradiol | 800 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 482 | Estradiol, Free | 275 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 483 | Estradiol, Ultrasensitive, LC/MS | 180 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 484 | Estrogens, Fractionated, LC/MS | 26 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 485 | Estrogens, Total, Immunoassay | 500 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 486 | Estrone | 140 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 487 | Ethambutol Level | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 488 | Ethosuximide | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 489 | Ethylene Glycol | 20 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 490 | Euglobulin Clot Lysis Time | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 491 | Everolimus, Blood | 15 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 492 | Exome with CNV Evaluation, Reanalysis | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 493 | Factor H (B1H) Level | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 494 | Factor II Activity, Clotting | 13 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 495 | Factor IX Activity and Human Inhibitor | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 496 | Factor IX Activity, Clotting | 16 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 497 | Factor IX Antigen | 4 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 498 | Factor V (Leiden) Mutation Analysis | 25 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 499 | Factor V Activity and Human Inhibitor | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 500 | Factor V Activity, Clotting | 45 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 501 | Factor VII Activity, Clotting | 15 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 502 | Factor VIII Activity, Chromogenic | 25 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 503 | Factor VIII Activity, Clotting | 170 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 504 | Factor VIII Antigen | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 505 | Factor VIII Inhibitor Panel | 15 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 506 | Factor X Activity, Chromogenic | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 507 | Factor X Activity, Clotting | 15 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 508 | FACTOR XI ACTIVITY&INHIB | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 509 | Factor XI Activity, Clotting | 16 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 510 | Factor XII Activity, Clotting | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 511 | Factor XIII, Functional | 7 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 512 | Familial Mediterranean Fever Mutation Analysis | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 513 | Fatty Acid Panel, Essential (C12-C22), Serum | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 514 | Fecal Fat, Qualitative | 450 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 515 | Fecal Fat, Total, Quantitative | 70 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 516 | Fecal Leukocyte Stain | 14 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 517 | Fentanyl and Norfentanyl | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 518 | Ferritin | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 519 | FGF 23 (Fibroblast Growth Factor 23) | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 520 | Fibrin Monomer | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 521 | Fibrinogen Activity, Clauss | 23 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 522 | Fibrinogen Antigen, Nephelometry | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 523 | Fibrinogen Degradation Products (FDP) | 20 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 524 | Filaria Antibody (IgG4) | 8 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 525 | FISH, ALK 2p23 Rearrangement, Lung Cancer (NSCLC) | 65 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 526 | FISH, ALL/NHL, MYC-BA, 8q24 Rearrangement | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 527 | FISH, AML, CBFB/MYH11, Inversion 16 | 60 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 528 | FISH, B-Cell Chronic Lymphocytic Leukemia Panel | 60 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 529 | FISH, B-Cell Malignancy, IGH, 14q32 Rearrangement | 30 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 530 | FISH, Burkitt's/NHL/ALL, IGH/MYC, t(8;14) | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 531 | FISH, CML/ALL, bcr/abl, Translocation 9,22 | 70 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 532 | FISH, Follicular Lymphoma, IGH/BCL2, t(14;18) | 15 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 533 | FISH, HER-2/neu with Reflex to IHC | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 534 | FISH, HER-2/neu, Paraffin Block | 15 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 535 | FISH, HES/Leukemia, 4q12 Rearrangement (FIP1L1-PDGFRA) | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 536 | FISH, High-Grade Lymphoma Panel | 45 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 537 | FISH, IGH/CCND1, t(11;14) | 16 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 538 | FISH, Locus-Specific Probe (x1) | 55 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 539 | FISH, Locus-specific Probe (x2) | 45 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 540 | FISH, Locus-Specific Probe (x3) | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 541 | FISH, MALT Lymphoma, API2/MALT1, t(11;18) | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 542 | FISH, MALT Lymphoma, MALT1, rea18q21 with Reflex to API2/MALT1, t(11;18) | 16 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 543 | FISH, MDM2 12q15/CEP 12 | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 544 | FISH, MDS/Myeloid Panel, -5/5q-, -7/7q-, +8,20q- | 85 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 545 | FISH, MET Amplification | 60 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 546 | FISH, Multiple Myeloma, 1q21 | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 547 | FISH, Myeloid Lymphoid Leukemia (MLL) (11q23), Gene Rearrangement | 50 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 548 | FISH, Myeloma, 17p-, rea 14q32 with Reflexes | 85 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 549 | FISH, Myeloproliferative Neoplasms (MPN) (Eosinophilia) | 15 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 550 | FISH, NHL, BCL6 3q27 Rearrangement | 13 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 551 | FISH, RET | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 552 | FISH, RUNX1T1/RUNX1 (ETO/AML1), Translocation (8;21) | 50 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 553 | FISH, SRY/X Centromere | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 554 | FISH, Chromosome-Specific Probe (x1) | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 555 | Flecainide | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 556 | FLT3 Mutation Analysis | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 557 | Fluconazole | 4 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 558 | Flucytosine, Serum/Plasma | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 559 | Fluoride, Serum/Plasma | 2 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 560 | Fluoxetine | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 561 | Fluphenazine, Serum/Plasma | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 562 | Folate, RBC | 55 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 563 | Folate, Serum | 23 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 564 | Formic Acid, Serum/Plasma | 3 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 565 | Francisella tularensis Antibody, IgM and IgG, ELISA, Serum | 5 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 566 | Fructosamine | 1670 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 567 | FTA-ABS | 165 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 568 | Fungal Identification, Molds | 55 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 569 | Fungal Isolate Identification | 25 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 570 | Fungal Sequencing, ITS Region | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 571 | Fungitell® (1-3)-ß-D-Glucan Assay | 676 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 572 | Fungitell® (1-3)-ß-D-Glucan Assay, Endpoint | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 573 | Gabapentin | 225 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 574 | Galactose-Alpha-1,3-Galactose (Alpha-Gal) IgE | 54 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 575 | Galectin-3 | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 576 | GALOP™ Autoantibody Test | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 577 | Gamma Glutamyl Transferase (GGT) | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 578 | Gastrin | 155 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 579 | GASTRIN W/INTERPRETATION | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 580 | GASTRIN,IHC W/O INTERP | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 581 | Gaucher Disease, DNA Mutation Analysis | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 582 | Gentamicin, Peak | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 583 | Gentamicin, Trough | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 584 | Giardia Antigen, EIA, Stool | 260 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 585 | Giardia and Cryptosporidium Antigen Panel | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 586 | Ginger (f270) IgE | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 587 | Gliadin (Deamidated) Antibody (IgA) | 15 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 588 | Gliadin (Deamidated) Antibody (IgG) | 45 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 589 | Gliadin (Deamidated) Antibody (IgG, IgA) | 330 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 590 | Glomerular Basement Membrane Antibody (IgG) | 160 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 591 | Glucagon | 28 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 592 | Glucose | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 593 | Glucose, Peritoneal Fluid | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 594 | Glucose, Pleural Fluid | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 595 | Glucose, Synovial Fluid | 50 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 596 | Glucose, Pericardial Fluid | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 597 | Glucose-6-Phosphate Dehydrogenase, Quantitative | 550 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 598 | Glutamic Acid Decarboxylase-65 Antibody | 650 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 599 | Glutethimide, Serum/Plasma | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 600 | Gold, Serum/Plasma | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 601 | Gonadotropin Releasing Hormone | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 602 | Growth Hormone (GH) | 100 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 603 | Haemophilus influenzae Type B Antibody (IgG) | 20 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 604 | Hairy Cell Leukemia (HCL)/Lymphoma Follow-up Panel | 1 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | |||||
| 605 | Haloperidol | 10 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 | $ - 0 |
This is the start of the file's text. The full file is on GovTribe.
File details come from the government source that posted it. Updated .